In CNS, breakthroughs do not come easily. They require total dedication to the science, the patients, and the realities of neuroscience drug development. Sponsors advancing these programs take on that challenge knowing the path is long, the science is unforgiving, and many of the conditions they are working to treat have been underserved for decades. They need a partner who matches that level of commitment, understands the nuances of their indications, and stays accountable for the outcome, not just the process.
In 2006, Cognitive Research Corporation (CRC) was founded to be that partner. Not because there were no CROs supporting CNS trials, but because the experience sponsors were navigating often fell short of what these programs deserved. CROs that overpromised and underdelivered. Treated clinical trials as transactional once the contract was signed, overlooked the value of consistency, and lacked the scientific depth and follow-through to back up what they sold. Sponsors were often forced to do the job they thought their CRO would handle – managing gaps, solving problems, and carrying more of the burden than they anticipated.
CRC was built on the belief that a better experience was possible with a team that genuinely cares and is relentless about delivering to the customer’s satisfaction. Sponsors deserve a CRO that is a true partner, not a vendor, but one equally committed to their success. That conviction has not changed in twenty years. It established our culture and continues to define how CRC operates today.
A COLLECTIVE EFFORT TO ADVANCE CNS RESEARCH
Twenty years of Bold Research is a milestone that extends beyond CRC. It reflects twenty years of sponsors who advanced complex programs from the lab through clinical development and eventual patient care. Teams that secured funding, built the evidence, and made the decision to move forward in a field where success is never guaranteed found an honest partner in CRC. It incorporated investigators and site teams who executed with rigor and care, and patients who chose to participate in research that may not benefit them directly but could change what is possible for others.
Every program CRC has supported has been part of a broader effort to move CNS treatments forward. That shared purpose is what allows Bold Research to take shape. It is not owned by one organization. It is carried forward by sponsors, sites, and partners working together to challenge the status quo, hold higher standards to ensure work is done the right way, and stay accountable to the mission. That collective commitment is what connects the work done across studies and what allows progress to build over time.
Across the last two decades, CRC has focused exclusively on building a model and team designed to support Bold Research in CNS. Processes and solutions are refined around the specific demands of neuroscience trials. Longstanding site relationships developed across hundreds of studies spanning neurology, psychiatry, and pain. Scientific, medical, and assessments expertise embedded in every program from the start, integrated with the project team rather than pulled in when challenges arise. Hands-on leadership invested in trial success with immediate availability to sponsors and sites. A team with an industry-high retention rate, so the people who understand a sponsor’s protocol, sites, and objectives remain engaged from the first conversation through the final deliverable.
The impact of twenty years focused on CNS, built on aligned partnership and a higher standard for delivery, shows up in the results. CRC has been fortunate to work alongside sponsors developing efficacious therapies, but positive trials still require rigorous, strategic execution. Across CRC-supported trials, 77% of Phase II trials and 73% of Phase III trials have yielded positive outcomes, with a 95% NDA approval rate across 20+ submissions.
BUILT TO MEET THE DEMANDS OF WHAT’S NEXT
CNS clinical development is advancing at a pace and scale the field has not previously seen. Programs are more scientifically ambitious, regulatory expectations continue to evolve, and competition for experienced sites and qualified patients is increasing. The margin for misalignment between sponsor, CRO, and site has narrowed accordingly.
The next wave of CNS clinical research demands more. Greater precision in study design, more thoughtful site selection and engagement, operational strategy informed by decades of experience, and consistent teams who understand the therapeutic area, anticipate the challenges, and take ownership of the outcome.
Everything built over the past twenty years has been in anticipation of what comes next: A foundation shaped by the realities of CNS development. An approach grounded in discipline, precision, and accountability. A commitment to raising expectations rather than meeting the minimum required.
That is what Bold Research means at CRC. Not as a tagline, but as a standard to which CRC has been holding since 2006. Twenty years in, CRC will never stop working to raise the standards, find better solutions, and rise to any occasion to support the bold innovators our team serves.
For sponsors advancing the next generation of CNS therapies, CRC brings the focus, the expertise, and the partnership to see it through.
CNS breakthroughs favor the bold. Build your legacy of CNS innovation boldly with CRC.
